Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-010489 Size: 9 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 8.01 Accession Number: 0001104659-22-004928 Act: 34 Size: 195 KB 网页链接
$Nabriva Therapeutics(NBRV)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-22-004924 Act: 34 Size: 38 KB 网页链接
$Nabriva Therapeutics(NBRV)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-22-004505 Act: 34 Size: 31 KB 网页链接
$Nabriva Therapeutics(NBRV)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-22-004424 Act: 34 Size: 44 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 8.01 Accession Number: 0001104659-22-004425 Act: 34 Size: 194 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-002736 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-002735 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 2.02, 8.01, and 9.01 Accession Number: 0001104659-22-002471 Act: 34 Size: 253 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 3.01 Accession Number: 0001104659-22-002311 Act: 34 Size: 198 KB 网页链接